Genetic Agency Technology Conference (GATC) 2025

Apply to attend

A one-day gathering for therapeutic developers, technologists, AI pioneers, and entrepreneurs, together with patients and their advocates, to co-create the future of genetic medicine

November 11, 2025
Boston Seaport (Westin)

Apply to attend

About GATC

We are working to build a world with “genetic agency”: an individual’s ability to take action at the genetic level to live a healthier life. It’s a term we’ve started using to highlight the importance of creating therapeutic options where none exist today, and to recognize the efforts of patients and their families who work to develop these medicines themselves rather than to give up hope. To help make this happen, Dyno is hosting a Genetic Agency Technology Conference (GATC) in Boston on November 11.

The conference is inspired by a vision of the future with patient-empowering genetic technologies that are safe, effective and accessible to all — and the recognition that we will need to overcome major challenges, technological and otherwise, for all of these treatments to become a reality. This future can’t be realized by any one actor alone — it requires a community working together with pace to turn powerful emerging technologies into patient impact.

At GATC we’re bringing together leaders from various sectors: therapeutic developers, technologists, AI pioneers, and entrepreneurs along with patients and their advocates. Topics at this meeting will include state of the art AI for sequence design, along with gene editing and gene delivery as enabling technologies, and other areas of interest to attendees such as preclinical development, manufacturing and regulatory pathways.

Compared to other conferences, GATC puts greater emphasis on technological frontiers, firmly grounded in patient impact and including highly participatory sessions emphasizing conversation and connnection. Our assumption is that everyone who attends comes with expertise and a goal.

Why Attend

Empower

Elevate the voices of patients and their advocates as critical experts shaping the next generation of genetic technologies

Connect

Build lasting relationships across the gene therapy ecosystem that are rooted in a shared commitment to advancing genetic agency

Engage

Spark meaningful and candid conversations to challenge norms and bridge the gap between technology innovation and real patient impact

Activate

Gain actionable insights to translate learnings into better treatment options today and goals for future technology development that align with patient priorities

Featured Speakers

Our exciting lineup of speakers includes:

George Church, PhD
Founding Core Faculty and Synthetic Biology Lead at the Wyss Institute
Sonia Vallabh, PhD
Director of Prion Therapeutic Science at the Broad Institute
Federico Mingozzi, PhD
CEO of Stealth Company and ASGCT Treasurer
Terence Flotte, MD
Provost, Dean, Professor at UMass Chan Medical School and ASGCT President
Victoria Gray
Patient advocate, first patient treated with CRISPR gene editing therapy for Sickle Cell Disease
James Wilson, MD, PhD
Founder and CEO of Gemma Biotherapeutics and Franklin Biolabs
Sylke Poehling, PhD
CEO of Spark Therapeutics (Roche wholly owned entity) and SVP, Global Head of Therapeutic Modalities at Roche
Allyson Berent, DVM, DACVIM
CSO of Foundation for Angelman Syndrome Therapeutics
Ava Amini
Principal Researcher at Microsoft
Andrew Giessel, PhD
Co-founder and CTO of Growth Signals
Aravind Asokan, PhD
Professor Duke University School of Medicine, serial biotech entrepreneur
Ben Deverman, PhD
Director of Vector Engineering at the Stanley Center for Psychiatric Research at the Broad Institute of MIT and Harvard
Cory Sago, PhD
Founder and CEO of Amplitude Therapeutics
Daniel Oliver, MBA
Founder and CEO at Rejuvenate Bio
Dan Gibbs, PhD
Co-founder and CEO of Cirsium Biosciences
David Levy-Booth, PhD
Head of Engineering at Dyno Therapeutics
Elahe Vedadi
Research Scientist at Google DeepMind
Emma West, PhD
Co-Founder and CEO at Digital Biology
Eunsu Hur, BS
Undergraduate Student at MIT
Floris Engelhardt
CEO and Co-Founder of Kano Therapeutics
Gaurav Venkataraman, PhD
Co-founder and CEO of Trisk Bio
Hilary Eaton, PhD
CBO of Profluent
Jacob Becraft, PhD
Co-founder and CEO of Strand Therapeutics
John Finn, PhD
CSO of Basecamp Research
Jonathan Gootenberg, PhD
Assistant Professor of Medicine at Harvard Medical School, Co-Director of the Abudayyeh-Gootenberg Lab, and Co-founder of multiple biotechs
Josh Leeman, PhD
Vice President Business Development/Search and Evaluation at UniQure
Kevin Davies
British Author and Editor, Editorial Director of GEN
Laura Lande-Diner, PhD
Managing Partner, Jefferson Life Sciences, serial biotech entrepreneur
Le Cong, PhD
Assistant Professor at Stanford University School of Medicine
Martin Borch Jensen, PhD
Co-founder and CSO of Gordian Biotechnology
Mathieu Nonnenmacher, PhD
VP of Gene Therapy at Voyager Therapeutics
Misha Glouberman
Conference Design & Experience Consultant for GATC 2025
Nima Alidoust, PhD
Co-Founder and CEO at Tahoe Therapeutics
Omar Abudayyeh, PhD
Assistant Professor of Medicine at Harvard Medical School, Co-Director of the Abudayyeh-Gootenberg Lab, and Co-founder of multiple biotechs
Pierce Ogden, PhD
Co-Founder and CTO of Manifold Bio
Pranam Chatterjee, PhD
Assistant Professor at University of Pennsylvania and Co-founder of multiple biotechs
Winston Yan, MD, PhD
Founding President of N=1 Collaborative and Co-founder of Arbor Biotechnologies
Yogev Debbi, MBA
Co-founder and CEO of Mana.bio

Schedule

November 11, 2025

8:00 am - 8:30 am
Registration, Breakfast and Coffee
Foyer
Grand A + B
8:30 am - 8:40am
Welcome and Opening Remarks
Eric Kelsic
Grand A + B
8:40 - 9:00am
How and Why to Cure Prion Disease
Sonia Vallabh
Grand A + B
9:00 - 9:45am
Genetic Agency Conversations
Misha Glouberman
Grand A + B
9:45 - 10:05am
Break
10:05 - 10:25am
Rare Disease Access to Gene Therapy: Update on ASGCT Role
Terence Flotte
Grand A + B
10:25 - 10:40 am
Dyno Therapeutics: Empowering Patients with Genetic Agency
Eric Kelsic
Grand A + B
10:40 - 10:50 am
Break
10:50 - 12:50 pm
Platform Sessions with Discussions
Broadening Patient Impact
Grand C
Introduction to Session
Tyson Bertmaring
Gene Therapy as a Disruptive Technology
Jim Wilson
Rethinking how we fund, build and sustain the next generation of therapies
Laura Lande-Diner
Genetic Surgery for Genetic Agency: building a procedural model for delivering ultra rare disease therapies
Winston Yan
Focal Administration of AAV Therapies for Severe Neurological Diseases
Josh Leeman
Silencing the Critics: Scaling Gene Therapy for Human and Animal Health
Dan Oliver
Solving Gene Delivery
Grand D
Dyno-bn8, safe and therapeutic gene delivery for muscle gene therapies
Adrian Veres
Circular single-stranded DNA: Building the next generation of genetic cargo
Floris Engelhardt
Shuttling precision genetic medicines into the CNS using human TfR1-binding AAV capsids
Ben Deverman
TRACER Capsid Platform for Systemic Gene Delivery to the CNS
Mathieu Nonnenmacher
Amplifying the promise of RNA medicines to empower genetic agency
Cory Sago
AI-powered drug delivery: Unlocking programmable science
Yogev Debbi
Redefining Gene Delivery Through Plant-Based Manufacturing
Daniel Gibbs
Manufacturing agency via scalable methods
Gaurav Venkataraman
Genetic Information & Intervention
Grand E
Introduction to Session
Eric Kelsic
AI-Programmable Gene Insertion: A Path to Genetic Agency for All
John Finn
Genetic medicine platforms at the AAV-RNA Interface
Aravind Asokan
Agency begins with knowing what to do
Martin Borch Jensen
Massively Multiplexed In Vivo Screening of AI-Designed Proteins Enables Programmable Tissue Targeting
Pierce Ogden
The future of genetic medicine: smarter platforms, broader access, deeper impact
Federico Mingozzi
Function-First Biologics Engineering in the Era of Genetic Agency
Emma West
Genetic agency through programmable biology tools
Jonathan Gootenberg & Omar Abudayyeh
Fireside Chat
Eric Kelsic, George Church & Kevin Davies
AI meets Genetic Agency
Commonwealth A+B
Introduction to AI for genetic agency
Sam Sinai
Accelerating the pace of scientific discovery
Daniel Burkhardt
Treating cancer like the polygenic disease that it is
Nima Alidoust
Modeling missense variants to gain insight into causal human biology
Hilary Finucane
Advancing Genetic Agency via Programmable Biologics
Pranam Chatterjee
BoltzGen: Toward Universal Binder Design
Hannes Stärk
Democratizing gene editing with AI
Hilary Eaton
Scaling generative models for functional protein design
Ava Amini
Code to Cure: Build Models, Agents, AI-XR Co-scientists to Drive Biomedical Innovation
Le Cong
Innovation and Genetic Agency in the Age of AI
Andrew Giessel
Panel Discussion: The role of AI agents in the future of discovery, development and technologies that enable genetic agency
Fay Lin, Le Cong, Andrew Giessel, Elahe Vedadi & David Levy-Booth
12:50 - 1:50pm
Buffet Lunch
Foyer
Grand A + B
1:50 - 2:10pm
AI & Genetic Agency
George Church
Grand A + B
2:10 - 2:30pm
Three Eras of Genetic Medicine: Creating the Path
Sylke Poehling
Grand A + B
2:30 - 3:40pm
Roundtable Conversations
For the detailed list of roundtable topics click here
Grand A + B
3:40 - 4:00pm
Break
4:00 - 4:30pm
Fireside Chat
Victoria Gray & Eric Kelsic
Grand A+B
4:30 - 4:50pm
The Parents’ Journey Through Drug Development: The Angelman Syndrome story of making the impossible possible
Allyson Berent
Grand A+B
4:50 - 5:20pm
Reflections and Closing
Eric Kelsic & Misha Glouberman
Grand A+B
5:20 - 7:00pm
Reception and Happy Hour
Foyer

FAQ

Where is GATC taking place?

Is the event in-person, virtual, or hybrid?

Is the event and venue accessible?

What are the best ways to get there?

Is there a dress code?

Will food be provided?

Is there Wi-Fi available onsite?

Will there be a way to connect with other attendees?

Interested in taking part in GATC 2025?

GATC is an invitation-only event, though a limited number of spots are available for those who apply to attend. We welcome anyone interested to submit an application, no later than Oct 10.

Apply to attend